anti-CD3/anti-EGFR bispecific T-cell engager Y-Body (Wuhan YZY Biopharma)

N/A

Report date: 2026/03/19 16:58:26

Base Information

Drug Nameanti-CD3/anti-EGFR bispecific T-cell engager Y-Body (Wuhan YZY Biopharma)
Drug Alias Nameanti-EGFR/anti-CD3 bispecific antibody Y-Body (Wuhan YZY Biopharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsT cell surface glycoprotein CD3 modulators
TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Yzy Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A